- NCIt
- C150572
Loading cancer entity…
Loading cancer entity…
Clinical trials
65 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (7)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04506554 | A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer | active not recruiting | Phase 2 | 81 | Fox Chase Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05406713 | Pembrolizumab in Muscle-invasive Bladder Cancer | active not recruiting | Phase 2 | 46 | Matthew GalskyOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT05975307 |
| Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation(BCIRT-01) |
| active not recruiting |
| Phase 2 |
| 71 |
| Sun Yat-sen UniversityOTHER |
| 1 |
| Dec 1, 2025 |
| clinicaltrials |
Data updated 5 days agoSource updated Sep 21, 2026source: clinicaltrials